Powering the Immune System to Transform Lives

Jeffrey S. Hatfield photoJeffrey S. Hatfield


Jeffrey S. Hatfield joined our Board in December 2020. 

Mr. Hatfield currently serves as Chairman of the Board for both Vividion Therapeutics, Inc., a chemoproteomics pioneer, and ROME Therapeutics, a biotech leading exploration of the dark genome.

Mr. Hatfield has more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. 

Among his many biotech leadership roles, Mr. Hatfield previously served as the CEO of Vividion Therapeutics, Inc., from 2020 through its arm’s length subsidiary model acquisition by Bayer, and until his retirement in Jan 2023, and for Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he worked from start-up until the company’s acquisition in 2016. 

Prior to his biotech career, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held various roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. 

Mr. Hatfield currently serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. 

Mr. Hatfield holds a B.S. from the Purdue University College of Pharmacy and an MBA from The Wharton School, University of Pennsylvania.